Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business & Finance
Essure developer reports record net sales, files updated label claims with FDA
May 26th, 2005
Conceptus, Inc., (CPTS), developer of the nonincisional permanent birth control procedure Essure, reported financial results for the 3 months ended March 31, 2005. Net sales for the first quarter of 2005 were $3.9 million, up 63% compared with net sales of $2.4 million for the first quarter of 2004 and up 7% compared with net sales of $3.6 million for the fourth quarter of 2004. These results exceeded the company's first-quarter net sales guidance of $3.5-3.7 million. The net loss for the first quarter of 2005 was $6.4 million, or $0.25 per share, compared with the net loss for the first quarter of 2004 of $7.1 million, or $0.31 per share, and was comparable to the net...
Source: Women's Health Weekly (2005-05-26)
|
